Delusional disorder: Molecular genetic evidence for dopamine psychosis

Neuropsychopharmacology

Volumn 26, Issue 6, 2002, Pages 794-801

  Morimoto, Kiyoshi ^a   Miyatake, Ryosuke ^a   Nakamura, Mitsuo ^a   Watanabe, Takemi ^a   Hirao, Toru ^a   Suwaki, Hiroshi ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Delusional disorder; Dopamine psychosis; DRD2 Ser311Cys; DRD3 Ser9Gly; pHVA; Polymorphism

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; HOMOVANILLIC ACID; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSION; DNA POLYMORPHISM; DOPAMINE PSYCHOSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; JEALOUSY; MALE; MOLECULAR GENETICS; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GENOTYPE; HOMOVANILLIC ACID; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA, PARANOID;

EID: 0036234575     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00421-3     Document Type: Article

References (66)

1. Association of dopamine D2 receptor molecular variant with schizophrenia
2. Further association study on dopamine D2 receptor variant S311C in schizophrenia and affective disorder
3. DRD2 Ser311/cys311 polymorphism in schizophrenia
4. Plasma Catecholamine metabolites and early response to haloperidol
5. Psychotic patients with increased plasma HVA and MHPG or increased HVA alone
6. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
7. The current status of the dopamine hypothesis of schizophrenia
8. Deficit and nondeficit forms of schizophrenia: The concept
9. Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection
10. Plasma homovanillic acid levels and subtyping of schizophrenia
11. No association of dopamine D2 receptor molecular variant Cys311 and schizophrenia on Chinese patients
12. Functional analysis of the human D2 dopamine receptor missense variants
13. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene
14. Molecular pathology of schizophrenia: More than one disease process?
15. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls
16. Plasma homovanillic acid concentration and the severity of schizophrenia illness
17. Dopamine in schizophrenia: A review and reconceptualization
18. Distribution of Mscl polymorphism of the dopamine D3 receptor in an Italian psychotic population
19. Meta-analysis of DRD3 gene and schizophrenia: Ethnic heterogeneity and significant association in Caucasians
20. Amphetamine psychosis I. Description of the individuals and process
21. The paranoid symptoms which appear in the latter half of life
22. Etiologic heterogeneity of the psychoses: Is there a dopamine psychosis?
23. No structural mutation in dopamine D2 receptor gene in alcoholism or schizophrenia
24. The neuropathology of schizophrenia: A critical review of the data and their interpretation
25. Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells
26. Methylphenidate, dextroamphetamine and levamfetamine. Effects on schizophrenic symptoms
27. Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene
28. Dopamine-related genes and their relationships to monoamine metabolites in CSF
29. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area
30. Plasma homovanillic acid levels in first episode schizophrenia. Psychopathology and treatment response
31. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
32. Imaging dopamine transmission in schizophrenia. A review and meta-analysis
33. The symptoms of schizophrenia. A re-examination of positive-negative dichotomy
34. Provocative tests with psychostimulant drugs in schizophrenia
35. Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the semliki forest virus system
36. Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia
37. A tetranucleotide polymorphic microsatellite, located in the first intron of the tyrosine hydroxylase gene, acts as a transcription regulatory element in vitro
38. An overview of treatment in paranoia/delusional disorder
39. First-episode neuroleptic-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment
40. DRD2 Ser311/Cys311 polymorphism in schizophrenia
41. Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples
42. A biomodal distribution of plasma HVA/MHPG in the psychoses
43. A chart review study of late-onset and early-onset schizophrenia
44. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
45. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment
46. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia
47. Late paraphrenia
48. No evidence for association of dopamine D2 receptor variant (Ser311/Cys 311) with major psychosis
49. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia
50. Antipsychotic drug dose and neuroleptics/dopamine receptors
51. Dopamine receptor D2 Ser/Cys311 is associated with delusion and disorganization symptomatology in major psychoses
52. DRD2 Ser311/cys311 polymorphism in schizophrenia
53. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia
54. Neurochemical brain imaging investigations of schizophrenia
55. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
56. European multicentre association study of schizophrenia: A study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms
57. Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia
58. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia
59. Association of polymorphic VNTR region in the first intron of the human Th gene with disturbances of the catecholamine pathway in schizophrenia
60. Possible association of catecholamine turnover with polymorphic (TCAT)n repeat in the first intron of the human tyrosine hydroxylase gene
61. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia
62. The dopamine hypothesis of schizophrenia: Current status, future prospects
63. Dopamine D2 densities and the schizophrenic brain